



National Institutes of Health
National Institute of Allergy and Infectious Diseases
Technology Transfer and Intellectual Property Office

Date: November 30, 2017

To: Knowledge Ecology International (KEI) and
Médecins Sans Frontières c/o KEI
1621 Connecticut Avenue, Suite 500
Washington, DC 20009

Subject: KEI Comments regarding 82 FR 47537, "Prospective Grant of Exclusive Patent License: DNA-based Vaccine for Prevention of Zika Virus Infection" notice – Prospective Exclusive Patent License to PaxVax, Inc.

Dear Ms. Treanor, Mr. Love, and Mr. Goldman,

I write to confirm receipt of your communications on October 25, 2017, November 7, 2017, and November 13, 2017. Thank you for providing comments in response to the recent *Federal Register* notice of a proposed exclusive license the National Institute of Allergy and Infectious Diseases (NIAID) intends to grant to PaxVax, Inc.

Prior to posting a notice for a proposed grant of an Exclusive Patent License, the NIAID determines that the criteria set forth in 37 CFR 404.7 have been satisfied with respect to granting the organization an exclusive license to the Government's intellectual property rights in the field of use as specified. The notice period provides an opportunity for public comments on and possible objection to the proposed license. Before negotiating the proposed license, we consider all comments received.

Best regards,

A handwritten signature in blue ink that reads "Amy Petrik".

Amy Petrik, Ph.D.
Technology Transfer and Patenting Specialist
Technology Transfer and Intellectual Property Office
National Institute of Allergy and Infectious Diseases
5601 Fishers Lane, Suite 6D
Rockville, MD 20892-9804